Literature DB >> 16406875

Effect of preoperative delay on survival in patients with bladder cancer undergoing cystectomy in Quebec: a population based study.

Salaheddin M Mahmud1, Brian Fong, Nader Fahmy, Simon Tanguay, Armen G Aprikian.   

Abstract

PURPOSE: In Canada there is growing concern that waiting time for cancer surgery has been increasing. We used population based data to estimate the average PD for RC in Quebec and assess whether delayed surgery has a negative impact on long-term survival.
MATERIALS AND METHODS: We used the provincial billing database of the maladie du Quebec to identify all patients with bladder cancer 18 years or older who underwent RAMQ from 1990 to 2002. PD was calculated as the time elapsed between the most recent transurethral resection and the date of RC. Patients were categorized according to PD tertiles into 3 groups, namely 1) 20 or less, 2) 21 to 47 and (C) 48 days or greater. Cox proportional hazards models were used to assess the effect of PD on overall survival, while adjusting for patient and provider factors.
RESULTS: During the study period 1,592 radical cystectomies were performed. Overall median PD was 33 days (95% CI 30 to 35). Median PD increased from 23 days in 1990 to 50 in 2002. After adjusting for calendar year, and patient and provider variables there were no significant differences in survival among the 3 delay categories. However, patients subject to greater than 12 weeks of delay were at 20% greater risk for dying (95% CI 1.0 to 1.5, p = 0.051).
CONCLUSIONS: In line with previous reports PD greater than 12 weeks seems to be associated with a worse long-term prognosis.

Entities:  

Mesh:

Year:  2006        PMID: 16406875     DOI: 10.1016/S0022-5347(05)00070-4

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  23 in total

Review 1.  Retrospective economic and outcomes analyses using non-US databases: a review.

Authors:  Lizheng Shi; Eric Q Wu; Meredith Hodges; Andrew Yu; Howard Birnbaum
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

2.  Perioperative chemotherapy: the case for adjuvant chemotherapy for muscle-invasive bladder cancer.

Authors:  Alan So
Journal:  Can Urol Assoc J       Date:  2008-06       Impact factor: 1.862

3.  Perioperative chemotherapy for muscle-invasive bladder cancer.

Authors:  Peter Black; Alan So
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

4.  Saving time is saving lives: a delayed lobectomy predicts poorer overall survival in patients with clinical stage IA squamous cell carcinoma of the lung.

Authors:  Ching Feng Wu; Yin-Kai Chao
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

5.  Urologist referral delay and its impact on survival after radical cystectomy for bladder cancer.

Authors:  F Santos; A Dragomir; W Kassouf; E Franco; A Aprikian
Journal:  Curr Oncol       Date:  2015-02       Impact factor: 3.677

6.  Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting.

Authors:  Wassim Kassouf; Armen Aprikian; Fred Saad; Rodney H Breau; Girish Kulkarni; David M Guttman; Ken Bagshaw; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Fadi Brimo; Peter Chung; Darrel Drachenberg; Yves Fradet; Niels Jacobsen; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Alex Zlotta; Neil Fleshner; D Robert Siemens; Peter C Black
Journal:  Can Urol Assoc J       Date:  2018-03-19       Impact factor: 1.862

7.  Effect of time to surgery on outcomes in stage I esophageal adenocarcinoma.

Authors:  Vignesh Raman; Oliver K Jawitz; Soraya L Voigt; Chi-Fu J Yang; Hanghang Wang; David H Harpole; Thomas A D'Amico
Journal:  J Thorac Cardiovasc Surg       Date:  2019-10-08       Impact factor: 5.209

8.  Bacillus calmette-guérin failures and beyond: contemporary management of non-muscle-invasive bladder cancer.

Authors:  H Barton Grossman; Michael A O'Donnell; Michael S Cookson; Richard E Greenberg; Thomas E Keane
Journal:  Rev Urol       Date:  2008

9.  A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience.

Authors:  Atreya Dash; Joseph A Pettus; Harry W Herr; Bernard H Bochner; Guido Dalbagni; S Machele Donat; Paul Russo; Mary G Boyle; Matthew I Milowsky; Dean F Bajorin
Journal:  Cancer       Date:  2008-11-01       Impact factor: 6.860

10.  Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.

Authors:  Wassim Kassouf; Armen Aprikian; Peter Black; Girish Kulkarni; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Tarik Alam; Fadi Brimo; Normand Blais; Chris Booth; Joseph Chin; Peter Chung; Darrel Drachenberg; Yves Fradet; Michael Jewett; Ron Moore; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Neil Fleshner; Fred Saad; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2016-02-08       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.